Research & Development
Enzo launches RNA gene expression platform for HPV
The platform's products combine sequence-specific probes with Enzo's LoopRNA in situ hybridization (ISH) technology, enabling the products to detect target genes in tissue or cell samples while preserving the morphology, Enzo said. This study of single cells within their native tissue environment, called spatial biology, helps scientists characterize and understand disease, Enzo added.
September 25, 2022
TTS, OmniPathology to offer oral HPV testing in L.A.
A throat swab enables the detection of 14 high-risk strains of HPV by pathologists at OmniPathology's high-complexity, CLIA-certified pathology laboratory in Pasadena, CA.
August 16, 2022
OmniPathology launches lab-developed test for HPV
The PCR-based test detects 14 high-risk strains of HPV, a virus with potential to progress to cancer. It is performed on a throat swab submitted for testing to OmniPathology's CLIA-certified laboratory in Pasadena, CA, and helps screen for oropharyngeal cancer and early premalignant lesions.
July 11, 2022
Bio-Techne launches HPV assay in Europe
RNAscope in situ hybridization (ISH) is a highly sensitive and specific spatial biology technology, Bio-Techne said.
July 5, 2022
Roche launches HPV self-sampling solution
The patient self-collects a sample while at a healthcare facility, following instructions provided by a healthcare worker. Then the clinically validated vaginal sample is analyzed with the Roche Cobas HPV test on one of its molecular instruments.
June 15, 2022
Seegene develops '3 Ct' assay for HPV infection
The Allplex HPV HR assay detects 14 high-risk HPV types that cause cervical cancer. The assay provides the individual Ct value of each cancer type, allowing quantitative analysis to determine the infection level. The test is expected to be launched in the first half of 2022.
April 26, 2022
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Enzo's HPV test approved by New York health department
Ampiprobe is the company's PCR-based test which can detect 14 high-risk HPV variants. The company said this approval positions it to pursue U.S. and international regulatory approvals.
April 18, 2022
FDA approves BD genotyping capabilities for HPV assay
The supplement expands the genotype reporting for BD's Onclarity HPV assay beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68, and 56/59/66. The assay will become the only FDA-approved assay to individually identify and report these genotype results, according to the company.
March 8, 2022
Blood test predicts recurrence of HPV-driven oropharyngeal cancer
The multi-institutional study, presented by Dr. Glenn Hanna from the Dana-Farber Cancer Institute, indicated that the biomarker test may detect recurrent disease earlier than imaging or
February 24, 2022
Hologic adds SARS-CoV-2 test to global testing project
Hologic launched GAI at the 2018 International AIDS Conference as an initiative to offer an all-inclusive pricing structure with no upfront cost or capital expenditure. In addition to the SARS-CoV-2 assay, the company offers other tests in the initiative, including tests for HIV-1, hepatitis B and C, and HPV.
January 4, 2022
BD launches new BD Cor molecular diagnostics system
The BD Cor system uses robotics and sample management software algorithms. It is modular, scalable, and designed to address multiple needs within clinical labs for expanding molecular testing and increasing testing volumes.
August 24, 2021
Mel-Mont validates self-sampling kit
Norwegian researchers tested the kit's performance in a group of 500 women at detecting rates of genital HPV infection compared to clinician-collected samples. The study found "fair agreement" of HPV positivity rates between the two methods, according to the authors. The study was published in BMC Infectious Diseases.
August 4, 2021
Page 1 of 3